CELZ (Creative Medical Technology Holdings) Tariff Resilience Score: 7/10 (As of Jul. 07, 2026)


CELZ Creative Medical Technology Holdings Inc CELZ
36 GF Score
Price $1.11
GF Value $0.32
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Creative Medical Technology Holdings Tariff Resilience Score?

Creative Medical Technology Holdings CELZ -4.96% 36 Tariff Resilience Score is 7 as of Jul. 07, 2026. GuruFocus rates CELZ with a GF Score™ of 36/100 and a GF Value™ of $0.32 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,369 Biotechnology companies, Creative Medical Technology Holdings ranks better than 90.36% on this metric.

Creative Medical Technology Holdings has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Creative Medical Technology Holdings has Medical technology company with limited direct exposure to tariffs. Primarily focused on domestic R&D and sales, reducing vulnerability to international trade disruptions.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Creative Medical Technology Holdings might have Highly Resilient.

Creative Medical Technology Holdings  (NAS:CELZ) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Creative Medical Technology Holdings Tariff Resilience Score Related Terms

CELZ vs FBLG, GLMD, ALZN: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Creative Medical Technology Holdings's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Creative Medical Technology Holdings Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Creative Medical Technology Holdings's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Creative Medical Technology Holdings's Tariff Resilience Score falls into.


CELZ
36GF Score
Creative Medical Technology Holdings Inc CELZ
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Creative Medical Technology Holdings (CELZ) has a Tariff Resilience Score of 7 as of Jul. 07, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Creative Medical Technology Holdings ranks #132 out of 1369 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Creative Medical Technology Holdings' Tariff Resilience Score too high?
Creative Medical Technology Holdings' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Creative Medical Technology Holdings' value of 7 is 75% above this industry median. Based on the distribution chart, Creative Medical Technology Holdings ranks #132 out of 1369 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Creative Medical Technology Holdings has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Creative Medical Technology Holdings' Tariff Resilience Score compare to FBLG and GLMD?
According to the Biotechnology industry distribution chart, Creative Medical Technology Holdings ranks #132 out of 1369 companies for Tariff Resilience Score. This places Creative Medical Technology Holdings in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Creative Medical Technology Holdings' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,369 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Creative Medical Technology Holdings's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creative Medical Technology Holdings's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creative Medical Technology Holdings stock overvalued right now?
Based on GuruFocus' analysis, Creative Medical Technology Holdings (CELZ) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.32, compared to a current price of $1.11 — trading 248.1% above its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Creative Medical Technology Holdings' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Creative Medical Technology Holdings (CELZ), the current Tariff Resilience Score is 7 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Creative Medical Technology Holdings (CELZ) Overvalued in 2026?

Based on GuruFocus' analysis, Creative Medical Technology Holdings stock appears to be overvalued. The current stock price of $1.11 is trading 248.1% above its estimated GF Value™ of $0.32. GuruFocus considers Creative Medical Technology Holdings to be Significantly Overvalued.

Key valuation signals for CELZ:

  • Tariff Resilience Score: 7
  • GF Value™: $0.32 vs. price of $1.11 (248.1% above fair value)
  • GF Score™: 36/100 with 4 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1369)

No single metric tells the full story. See the CELZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Creative Medical Technology Holdings Business Description

Address 211 E Osborn Road, Phoenix, AZ, USA, 85012
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
36GF Score

Get the complete analysis for CELZ

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.11
Price
$0.32
GF Value